{"entity":{"id":"imp1734","kind":"drug","name":"IMP1734","aka":["EIK1003"],"tldr":"EIK1003, formerly IMP1734, is an experimental pill that blocks the PARP1 DNA-repair enzyme.","summary":"Eikon identifies EIK1003 as the former IMP1734 programme. NCT06253130 is a recruiting phase 1/2 study in advanced solid tumours. The sponsor describes PARP1 selectivity; this does not establish clinical superiority or an approved biomarker population. The asset and its licensing alias are one programme, distinct from EIK1004/IMP1707 and the WRN inhibitor EIK1005.","status":"phase-2","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov: trials of IMP1734","url":"https://clinicaltrials.gov/search?intr=IMP1734"},{"label":"ClinicalTrials.gov NCT06253130","url":"https://clinicaltrials.gov/study/NCT06253130"},{"label":"Eikon licensing identities","url":"https://www.eikontx.com/news/eikon-therapeutics-to-provide-corporate-updates-at-the-42nd-annual-j-p-morgan-healthcare-conference/"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":["eikon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06253130"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"IMP1734","modality":"Small-molecule inhibitor","mechanism":"PARP1-selective inhibitor and trapper, licensed as EIK1003.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/imp1734/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"}],"trial":[{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/"}]}}